Maze Therapeutics (MAZE) Stock Overview
A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MAZE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Maze Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.75 |
| 52 Week High | US$53.65 |
| 52 Week Low | US$9.73 |
| Beta | 0 |
| 1 Month Change | 0.23% |
| 3 Month Change | -41.77% |
| 1 Year Change | 153.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 61.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAZE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.6% | 1.9% | -0.8% |
| 1Y | 153.2% | 41.8% | 27.1% |
Return vs Industry: MAZE exceeded the US Pharmaceuticals industry which returned 38.7% over the past year.
Return vs Market: MAZE exceeded the US Market which returned 26.7% over the past year.
Price Volatility
| MAZE volatility | |
|---|---|
| MAZE Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MAZE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MAZE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 141 | Jason Coloma | www.mazetx.com |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
Maze Therapeutics, Inc. Fundamentals Summary
| MAZE fundamental statistics | |
|---|---|
| Market cap | US$1.39b |
| Earnings (TTM) | -US$122.54m |
| Revenue (TTM) | US$20.00m |
Is MAZE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAZE income statement (TTM) | |
|---|---|
| Revenue | US$20.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$20.00m |
| Other Expenses | US$142.54m |
| Earnings | -US$122.54m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 100.00% |
| Net Profit Margin | -612.71% |
| Debt/Equity Ratio | 11.4% |
How did MAZE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 08:56 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maze Therapeutics, Inc. is covered by 12 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Ananda Ghosh | H.C. Wainwright & Co. |